--- title: "Deadline to file claim in $30M settlement over 23andMe data breach nears" type: "News" locale: "en" url: "https://longbridge.com/en/news/276055499.md" description: "The deadline to file a claim in a $30 million settlement over a data breach at 23andMe is approaching, with claims due by February 17, 2026. The breach, caused by a credential stuffing attack, compromised the data of 6.9 million users. Affected individuals must have been members between May 1 and October 1, 2023, and notified of the breach. Payments vary, with $165 for those whose health information was impacted, and potential extraordinary claims up to $10,000. Payments will be distributed after the bankruptcy process is resolved." datetime: "2026-02-16T12:06:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276055499.md) - [en](https://longbridge.com/en/news/276055499.md) - [zh-HK](https://longbridge.com/zh-HK/news/276055499.md) --- # Deadline to file claim in $30M settlement over 23andMe data breach nears (NEXSTAR) – The deadline to claim part of a $30 million settlement in a lawsuit against 23andMe is drawing near. In the fall of 2023, the genetic testing and biotech company announced its site had been the victim of a “credential stuffing attack.” A class action lawsuit was subsequently filed against 23andMe. In September 2024, the company confirmed to Nexstar that it had proposed a $30 million settlement agreement in the case. Months later, in March 2025, 23andMe filed for bankruptcy. A judge in July approved the sale of 23andMe to TTAM Research Institute, a genetics-led healthcare company based in California and led by 23andMe co-founder and former CEO Anne Wojcicki. Now, you have only days to file a claim in the class action lawsuit. ### Who qualifies for the 23andMe settlement? Those impacted by the data breach qualify for a payment. More specifically, you had to have been a member between May 1, 2023, and October 1, 2023, and lived in the U.S. during that time. You must also have been notified that your personal information was “compromised” in the attack. ### What happened during the data breach? During the “credential stuffing attack,” hackers were able to use login credentials – allegedly obtained via a previous hack of an unrelated website – to access its customers’ accounts. In the months that followed, 23andMe confirmed that “threat actors” were able to access about 14,000 accounts, through which the data of 6.9 million users was compromised. Much of that data belonged to users who opted into the DNA Relatives feature, which allows users to share certain personal information with other users considered their genetic relatives. A class-action lawsuit subsequently filed against 23andMe accused the site of failing to protect users, Reuters reported. The lawsuit also alleged that much of the stolen data belonged to Jewish and Chinese users, possibly in a targeted attack, according to the outlet. ### How do I submit a claim? You can submit a claim online or via mail using the class member ID included in the notice you received. ### When is the deadline to submit a claim? For most, the deadline to submit a claim is 11:59 p.m. CT on Tuesday, February 17. However, if you first received a notice about the settlement on January 5, 2026, your deadline to apply is Sunday, March 1, 2026, according to court documents. ### How much will I receive? It depends. Those who were notified that their health information was impacted by the breach will receive $165, according to court documents. If you were impacted, settlement administrators say you need only to provide your preferred payment method to receive payment. If you are hoping to receive any other benefits, you’ll need to submit a claim form. That could include a Statutory Cash Claim. This is only for those who lived in Alaska, California, Illinois, or Oregon during the data breach and were notified that their information was compromised. These payments are estimated to be about $100, but could increase or decrease based on the number of valid claims. You’ll need to submit a claim form for the Statutory Cash Claim. Extraordinary claims could be worth up to $10,000 in cash. To qualify, you’ll need to provide evidence of losses or expenses incurred as a result of the breach. Claimants can also enroll in five years of “Privacy & Medical Shield + Genetic Monitoring,” according to settlement administrators. ### When will I receive my payment? It could take some time. According to the settlement administrators, payments won’t be disbursed until 23andMe’s bankruptcy reconciliation process is resolved. This “is likely to take considerable time,” the settlement site reads. The case docket shows additional court cases are set for Tuesday and March 18. You can find more details about the settlement here. ### Can I delete my 23andMe data? Yes, you can find details on those steps here. This option will remain available “in perpetuity,” according to settlement administrators. ### Related Stocks - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [LABD.US](https://longbridge.com/en/quote/LABD.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [ME.US](https://longbridge.com/en/quote/ME.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) ## Related News & Research - [23andMe data breach victims deserve $46.75 million payout, bankruptcy administrator says](https://longbridge.com/en/news/289517783.md) - [Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline | LIMN Stock News](https://longbridge.com/en/news/287218720.md) - [GRI Bio Highlights Promising Phase 2a IPF Data, Outlook](https://longbridge.com/en/news/286422240.md) - [HC Wainwright Analysts Increase Earnings Estimates for CTMX](https://longbridge.com/en/news/286258226.md) - [Immix Biopharma Announces 95% Complete Response Rate In Interim Update From Relapsed/Refractory AL Amyloidosis Clinical Trial NEXICART-2](https://longbridge.com/en/news/287200923.md)